Recent advances in ischemic stroke management.
10.5124/jkma.2016.59.10.775
- Author:
Cindy W YOON
1
;
Joung Ho RHA
Author Information
1. Department of Neurology, Inha University School of Medicine, Incheon, Korea. jhrha@inha.ac.kr
- Publication Type:Original Article
- Keywords:
Stroke;
Tissue plasminogen activator;
Endovascular procedures;
Platelet aggregation inhibitors;
Anticoagulants
- MeSH:
Anticoagulants;
Atrial Fibrillation;
Endovascular Procedures;
Platelet Aggregation Inhibitors;
Secondary Prevention;
Stroke*;
Tissue Plasminogen Activator
- From:Journal of the Korean Medical Association
2016;59(10):775-784
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
There have been recent advances in the hyperacute treatment and secondary prevention of ischemic stroke. Thrombolysis with intravenous tissue plasminogen activator has been approved for a 3 to 4.5 hour time window, but the recent controversy over the optimal dose has not been resolved. Five endovascular trials published in 2015 have shown dramatically positive results. Regarding secondary prevention of ischemic stroke, a study suggesting the beneficial effect of a short course of dual antiplatelet therapy has been published. Non-vitamin K antagonist oral anticoagulation agents have been approved for stroke prevention in non-valvular atrial fibrillation. Here, we review these recent advances in ischemic stroke management.
